Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SPRB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSpruce Biosciences holds routine 2026 Annual Meeting, re-elects directors through 2029
Filed May 26, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
low
Shareholders re-elected three Class III directors (Michael Grey, Camilla V. Simpson, and Javier Szwarcberg) to serve until the 2029 Annual Meeting with no changes to board composition.
Item 5.07 verify on EDGAR → -
low
BDO USA, P.C. ratified as independent auditor for fiscal 2026 with 98% approval (880,984 for vs 16,851 against), continuing existing auditor relationship.
Item 5.07 verify on EDGAR → -
low
Annual say-on-pay votes on executive compensation will continue yearly through 2032 following shareholder preference, a routine governance practice.
Item 5.07 verify on EDGAR → -
low
Meeting achieved 65.86% quorum with 903,893 of 1,372,278 outstanding shares represented, sufficient for conducting official business.
Item 5.07 verify on EDGAR →
Summary
Spruce Biosciences filed a routine 8-K disclosing results from its May 21, 2026 Annual Meeting of Stockholders. The meeting proceeded without surprises: all three incumbent Class III directors were re-elected to three-year terms, the existing auditor BDO USA was ratified with overwhelming support, and shareholders voted to continue annual advisory votes on executive compensation.
With nearly 66% of shares represented, the meeting had sufficient participation for all proposals to pass. For retail investors, this filing contains no material business developments or governance changes. The board composition remains stable, there is no auditor change that might signal accounting concerns, and executive compensation oversight continues as expected.
These are standard annual housekeeping matters required by securities regulations. Investors should watch for the company's upcoming proxy statement and 10-Q filings for substantive updates on Spruce's clinical pipeline and financial position, as this 8-K provides no insight into business operations or strategy.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
SPRB held its 2026 Annual Meeting with 65.86% quorum, electing three Class III directors and ratifying auditor BDO USA, P.C.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
As of March 24, 2026, the record date for the Annual Meeting, there were 1,372,278 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting, of which 903,893 shares, representing approximately 65.86% of the outstanding shares, were present virtually or represented by proxy, constituting a quorum.
The Annual Meeting achieved quorum with approximately 65.86% of outstanding shares represented. This is a routine procedural disclosure confirming sufficient shareholder participation to conduct official business.
Added in current filing · verify on EDGAR →
In light of the foregoing voting results, and consistent with the recommendation of the Board of Directors, the Company has determined that it will include a non-binding stockholder advisory vote on the compensation of the Company’s named executive officers in its proxy materials every year until the next required vote on the frequency of such advisory votes, which is required to occur no later than the Company’s 2032 Annual Meeting of Stockholders.
The company will hold annual say-on-pay votes on executive compensation through 2032, following shareholder preference (297,804 votes for annual frequency). This is a routine governance matter with no immediate financial impact.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify